Paper70689
Immunoglobulin-containing cells in multiple-sclerosis plaques.
Esiri MM. Lancet, 1977. Cited by 128 papers, by iCite.
Cite this record
ConductScience Library. Immunoglobulin-containing cells in multiple-sclerosis plaques. Papers, record 70689. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/70689
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibody-Producing Cells | Major topic |
| Immunoglobulin Heavy Chains | Major topic |
| Immunoglobulin Light Chains | Major topic |
| Multiple Sclerosis | Major topic |
| Adult | |
| Aged | |
| Cell Count | |
| Female | |
| Humans | |
| Immunoenzyme Techniques | |
| Immunoglobulin A | |
| Immunoglobulin G | |
| Immunoglobulin M | |
| Male | |
| Middle Aged |
Source PubMed
Cited by49
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 128 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41583430 | Plasma cells in and around the central nervous system. | Front Immunol | 2025 | https://conductscience.org/library/papers/41583430 | PubMed |
| 37274830 | Antibodies from serum and CSF of multiple sclerosis patients bind to oligodendroglial and neuronal cell-lines. | Brain Commun | 2023 | https://conductscience.org/library/papers/37274830 | PubMed |
| 36238195 | Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis. | Drug Des Devel Ther | 2022 | https://conductscience.org/library/papers/36238195 | PubMed |
| 34075251 | B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. | Nat Rev Neurol | 2021 | https://conductscience.org/library/papers/34075251 | PubMed |
| 33625628 | Main Role of Antibodies in Demyelination and Axonal Damage in Multiple Sclerosis. | Cell Mol Neurobiol | 2022 | https://conductscience.org/library/papers/33625628 | PubMed |
| 33504635 | Absence of B Cells in Brainstem and White Matter Lesions Associates With Less Severe Disease and Absence of Oligoclonal Bands in MS. | Neurol Neuroimmunol Neuroinflamm | 2021 | https://conductscience.org/library/papers/33504635 | PubMed |
| 32785877 | Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015-2020. | BioDrugs | 2020 | https://conductscience.org/library/papers/32785877 | PubMed |
| 31675681 | Pathogenic memory plasma cells in autoimmunity. | Curr Opin Immunol | 2019 | https://conductscience.org/library/papers/31675681 | PubMed |
| 31590282 | Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs-A Systematic Review. | J Clin Med | 2019 | https://conductscience.org/library/papers/31590282 | PubMed |
| 29719400 | New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab. | Neuropsychiatr Dis Treat | 2018 | https://conductscience.org/library/papers/29719400 | PubMed |
| 29273846 | Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor? | J Neurol | 2018 | https://conductscience.org/library/papers/29273846 | PubMed |
| 28450895 | Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. | Ther Adv Neurol Disord | 2017 | https://conductscience.org/library/papers/28450895 | PubMed |
| 26788129 | Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. | Ther Adv Neurol Disord | 2016 | https://conductscience.org/library/papers/26788129 | PubMed |
| 24808182 | Lipocalin-2 protein deficiency ameliorates experimental autoimmune encephalomyelitis: the pathogenic role of lipocalin-2 in the central nervous system and peripheral lymphoid tissues. | J Biol Chem | 2014 | https://conductscience.org/library/papers/24808182 | PubMed |
| 23766567 | Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis. | Mediators Inflamm | 2013 | https://conductscience.org/library/papers/23766567 | PubMed |
| 23594958 | Expansion of CD27high plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation. | Genes Immun | 2013 | https://conductscience.org/library/papers/23594958 | PubMed |
| 22644089 | Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature. | Clin Rheumatol | 2012 | https://conductscience.org/library/papers/22644089 | PubMed |
| 22132878 | Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system? | Clin Exp Immunol | 2012 | https://conductscience.org/library/papers/22132878 | PubMed |
| 21846731 | Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. | Brain | 2011 | https://conductscience.org/library/papers/21846731 | PubMed |
| 21142258 | The potential role of B cell-targeted therapies in multiple sclerosis. | Drugs | 2010 | https://conductscience.org/library/papers/21142258 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/70689
GET https://conductscience.org/api/papers/v1/70689/cited_by?page=2